Gudcef-XL 200 New Tablet ER is a combination antibiotic formulation containing Cefpodoxime Proxetil 200 mg and Dicloxacillin 500 mg, designed for extended-release administration. Cefpodoxime Proxetil, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of Gram-positive and Gram-negative pathogens. Dicloxacillin, a penicillinase-resistant penicillin, specifically targets penicillinase-producing Staphylococcus aureus, providing potent activity against beta-lactamase-producing Gram-positive bacteria. The extended-release formulation ensures sustained plasma concentrations, enhancing therapeutic efficacy and improving patient compliance by reducing dosing frequency. Gudcef-XL 200 New Tablet ER is indicated for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and bone infections caused by susceptible organisms. It is essential to use this medication under medical supervision with appropriate culture and sensitivity testing to prevent resistance development. Caution is advised in patients with a history of hypersensitivity to beta-lactam antibiotics. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, hematologic abnormalities. Dose adjustment may be necessary in renal impairment. This combination therapy offers a synergistic approach to managing mixed infections and resistant bacterial strains.